[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
About Journal::
Editorial Board::
Articles Archive::
Indexing Databases::
To Authors::
To Reviewers::
Submit Your Article::
Policies and Publication Ethics::
Archiving Policy::
Site Facilities::
Contact Us::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Registered in



:: Volume 2, Issue 3 (8-2015) ::
2015, 2(3): 31-41 Back to browse issues page
Vortioxetine versus placebo for treatment of major depressive disorder
Masoud Behzadifar , Hamidreza Dehghan , Kourosh Saki , Kourosh Sayehmiri , Meysam Behzadifar , Ali Akbari Sari
4. Department of Health Management and Economics, Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, Iran , masoudbehzadifar@gmail.com
Abstract:   (4188 Views)
Introduction: Major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options available in this important area of therapeutics. Materials and methods: A comprehensive literature search (PubMed, the Cochrane library, Scopus, CRD and HTA Database in January 2015) was performed, containing controlled clinical trials that vortioxetine 10 mg/d versus placebo in adults with major depressive disorder. Results: Six controlled clinical trials were included in this meta-analysis. There was a significant difference between the vortioxetine 10 mg/d versus placebo in the Montgomery–Åsberg Depression Rating Scale (MADRS) (P value <0.00001). The results of pooled analysis for diarrhea, dry mouth, dizziness, headache and nausea were also significant (P value <0.00001). Vortioxetine 10 mg/d versus placebo showed a significant difference for nausea, but no significant differences were observed for the other five adverse effects. Conclusion: Therapy with vortioxetine was significantly associated with reduction in depression symptoms from baseline compared to placebo.
Keywords: Vortioxetine 10 mg/d, Systematic Review, Meta-analysis, Major Depressive Disorder
Full-Text [PDF 780 kb]   (1198 Downloads)    
Type of Study: Review Article | Subject: Psychology
Received: 2015/03/11 | Accepted: 2015/08/16 | Published: 2015/09/9
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Behzadifar M, Dehghan H, Saki K, Sayehmiri K, Behzadifar M, Akbari Sari A. Vortioxetine versus placebo for treatment of major depressive disorder. Journal of Basic Research in Medical Sciences 2015; 2 (3) :31-41
URL: http://jbrms.medilam.ac.ir/article-1-96-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 2, Issue 3 (8-2015) Back to browse issues page
مجله ی تحقیقات پایه در علوم پزشکی Journal of Basic Research in Medical Sciences
Persian site map - English site map - Created in 0.09 seconds with 41 queries by YEKTAWEB 4654